

MCQOPTIONS
Saved Bookmarks
1. |
Phase 2 trial of new cancer drug. Which is least likely to account for variation in results: |
A. | Size of metastases |
B. | Site of metastases |
C. | Gender |
D. | Performance status |
E. | Prior therapy |
Answer» D. Performance status | |